Residual Kidney Function and Prevention of Cardiovascular Risk – Have We Said It All?

7th International Congress of Cardionephrology KARNEF (2025) [pp. 92-102]

AUTHOR(S) / АУТОР(И): Zorica M. Dimitrijevic 

Download Full Pdf   

DOI: 10.46793/KARNEF25.095D

ABSTRACT / САЖЕТАК:

Chronic kidney disease (CKD) has a strong association with increased cardiovascular (CV) risk, and residual kidney function (RKF) has recently been recognized as a key determinant of this burden. Through the removal of fluids and uremic toxins, modulation of systemic inflammation, and improved metabolic stability, RKF is linked to better cardiovascular outcomes. Despite advances in pharmacological therapies, dialysis innovation, and lifestyle interventions, patients with CKD still generally experience increased CVD mortality. This highlights the necessity of evaluating the multifactorial function of RKF in CV risk reduction.

It highlights processes and pathophysiological mechanisms linking RKF and CV health, especially with its role in systemic inflammation, oxidative stress, and regulation of volume. Data from several large clinical trials suggest the benefit of RKF preservation, including lower arterial stiffness, better BP control, and lower left ventricular hypertrophy (LVH) and CV mortality. Presently, pharmacological approaches are recommended to prevent the progression of RKF (e.g.,sodium-glucose co-transporter-2 (SGLT2) inhibitors and renin-angiotensin-aldosterone system (RAAS) blockers), along with lifestyle changes as well as advances in dialysis technology (e.g., incremental and peritoneal dialysis). Novel strategies like regenerative therapies and muscle biomarkers bring hope for personalized care.

This paper provides a roadmap for enhancing our understanding of and approach to CKD care by drawing attention to the role of RKF in preventing CV risk and knowledge gaps in the field. In essence, inventive strategies are needed to realize RKF’s capacity to enhance cardiovascular outcomes.“

KEYWORDS / КЉУЧНЕ РЕЧИ:

residual kidney function, cardiovascular disease, CKD, dialysis, risk prevention

REFERENCES / ЛИТЕРАТУРА:

  • Liu X, Dai C. Advances in understanding and management of residual renal function in patients with chronic kidney disease. Kidney Dis (Basel). 2017;2(4):187-196. doi:10.1159/000449029.
  • Kalantar-Zadeh K, Kopple JD. Residual kidney function in hemodialysis patients: implications for cardiovascular outcomes. Am J Kidney Dis. 2001;38(3):379-380.
  • Ebert T, Neytchev O, Witasp A, Kublickiene K, Stenvinkel P, Shiels PG. Inflammation and Oxidative Stress in Chronic Kidney Disease and Dialysis Patients. Antioxid Redox Signal. 2021 Dec 10;35(17):1426-1448. doi: 10.1089/ars.2020.8184. Epub 2021 Jul 30.
  • Caillard P, Bennis Y, Six I, Bodeau S, Kamel S, Choukroun G, et al. The Role of Gut-Derived, Protein-Bound Uremic Toxins in the Cardiovascular Complications of Acute Kidney Injury. Toxins (Basel). 2022 May 11;14(5):336. doi: 10.3390/toxins14050336.
  • Collister D, Ferguson TW, Funk SE, Reaven NL, Mathur V, et al. . Metabolic Acidosis and Cardiovascular Disease in CKD. Kidney Med. 2021 Jun 27;3(5):753-761.e1. doi: 10.1016/j.xkme.2021.04.011.
  • Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis. 2010;56:348–358. doi: 10.1053/j.ajkd.2010.03.020..
  • Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int. 2009;75(9):890-897.
  • Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol. 2004;24(5):469-473.
  • Zoccali C, Moissl U, Chazot C, Mallamaci F, Tripepi G, Arkossy O, et al. Chronic fluid overload and mortality in ESRD. J Am Soc Nephrol. 2017;28(8):2491-2497. doi:10.1681/ASN.2016121341.
  • London GM. Arterial and cardiac consequences of secondary hyperparathyroidism in end-stage renal disease. Nephrol Dial Transplant. 2002;17(11):2129-2132.
  • Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478-1483.
  • Block GA, Hulbert-Shearon TE, Levin NW, Port FK, Held PJ, Bloembergen WE, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218.
  • Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K, Waddup G, et al. Residual renal function improves outcomes in incremental hemodialysis. Am J Nephrol. 2009;30(5):515-523.
  • Wang AY, Wang M, Woo J, Lam CW, Lui SF, Sanderson JE, et al. Residual renal function and mortality risk in peritoneal dialysis patients. Am J Kidney Dis. 2004;43(5):836-846.
  • Kraut JA, Madias NE. Metabolic acidosis of CKD: an update. Am J Kidney Dis. 2010;56(4):762-771.
  • Termorshuizen F, Korevaar JC, Dekker FW, Van Manen JG, Boeschoten EW, Krediet RT, et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients. Kidney Int. 2004;66(3):1212-1220.Wang AY, Woo J, Wang M, et al. Impact of residual renal function on cardiovascular outcomes in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2004;15(2):728-735.
  • Obi Y, Raimann JG, Kalantar-Zadeh K, Murea M. Residual kidney function in hemodialysis: its importance and contribution to improved patient outcomes. 2024;16(7):298. doi:10.3390/toxins16070298.
  • Zoccali C, Moissl U, Chazot C, Tripepi G, Arkossy O, Wabel P, et al. Prognostic value of inter-dialytic weight gain and its modification by residual kidney function in dialysis patients. Nephrol Dial Transplant. 2002;17(7):1250-1257.
  • London GM, Guerin AP, Marchais SJ, Pannier B, Adda H, Benetos A, et al. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial. 2001;14(2):85-90.
  • Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int Suppl. 2006;70:S13-S17.
  • Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced repetitive myocardial injury. Clin J Am Soc Nephrol. 2009;4(5):914-920.
  • Stenvinkel P, Alvestrand A, Boslo T, Heimbürger O, Wanner C, Metzger T, et al. Emerging role of inflammation in chronic kidney disease: protein-energy wasting and cardiovascular disease. Nephrol Dial Transplant. 2005;20(12):2604-2612.
  • Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol. 2004;24(5):469-473.
  • Meyer TW, Hostetter TH. Uremic solutes: toxicity and vascular disease. Semin Dial. 2007;20(2):139-147.
  • Pecoits-Filho R, Heimbürger O, Bárány P, Lindholm B, Stenvinkel P, Alvestrand A, et al. Associations between residual kidney function and cardiovascular outcomes in dialysis patients. Nephrol Dial Transplant. 2003;18(4):885-891.
  • Davies SJ, Phillips L, Naish PF, Russell GI. Longitudinal relationship between residual kidney function and patient outcomes on peritoneal dialysis. Kidney Int. 2001;59(2):737-746.
  • Bargman JM, Thorpe KE, Churchill DN. Residual renal function: a paradigm shift in the CANUSA study. J Am Soc Nephrol. 2001;12(10):2158-2162.
  • Rangaswami J, Rao S, McCullough PA, Mohan S, Smith M, Wilson F, et al. Cardiac remodeling and outcomes after kidney transplantation. Am J Kidney Dis. 2015;66(2):344-351.
  • Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
  • Ruggenenti P, Remuzzi G. RAAS inhibitors in CKD: mechanisms and efficacy. Kidney Int Suppl. 2010;78(3):S20-S28.
  • Heerspink HJL, Stefánsson BV, Correa-Rotter R, Jongs N, Chertow GM, Greene T, et al. SGLT2 inhibitors and renal outcomes in CKD. Lancet Diabetes Endocrinol. 2022;8(7):582-591.
  • Chazot C, Jean G. Preservation of residual renal function in dialysis patients. Kidney Int. 2010;77(1):59-71.
  • Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845.
  • Navarro-Gonzalez JF, Mora-Fernandez C, Muros M, Garcia J, Martinez M, de Fuentes MM, et al. Anti-inflammatory effects of pentoxifylline in CKD patients. Clin J Am Soc Nephrol. 2009;4(2):391-398.
  • Fouque D, Vennegoor M, ter Wee P, de Charro F, van der Veen J, Argiles A, et al. Low-protein diets for CKD patients. Am J Kidney Dis. 2007;49(3):569-580.
  • Fouque D, Laville M. Dietary recommendations in CKD: advances in 2022. Clin Nutr.
  • Wathanavasin W, Kittiskulnam P, Johansen KL. Plant-based diets in patients with chronic kidney disease. Asian Biomed (Res Rev News). 2024;18(1):2-10. doi:10.2478/abm-2024-0002.
  • Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD, Mehrotra R, et al. Fluid balance and residual kidney function preservation. Kidney Int Suppl. 2015;87(4):977-989.
  • Perazella MA. Nephrotoxicity of NSAIDs. Clin J Am Soc Nephrol. 2009;4(3):556-562.
  • Caravaca F, Alcázar JM. Incremental dialysis and residual kidney function preservation. Clin Kidney J. 2021;14(2):1-9.
  • Mathew AT, Obi Y, Rhee CM, Chou JA, Kalantar-Zadeh K. Incremental dialysis for preserving residual kidney function: does one size fit all when initiating dialysis? Semin Dial. 2018;31(4):343-352. doi:10.1111/sdi.12701.
  • Vilar E, Wellsted D, Chandna SM, Greenwood RN, Farrington K, Waddup G, et al. Hemodynamic stability and residual kidney function preservation in HD. Am J Nephrol. 2009;30(5):515-523.
  • Bargman JM, Thorpe KE, Churchill DN. Residual renal function in peritoneal dialysis. J Am Soc Nephrol. 2001;12(10):2158-2162.
  • Flythe JE, Kimmel SE, Brunelli SM. Intradialytic hypotension and outcomes. Clin J Am Soc Nephrol. 2015;10(1):147-156.
  • Coca SG, Singanamala S, Parikh CR. Biomarkers of acute kidney injury. Kidney Int. 2008;73(6):791-800.
  • Tögel F, Westenfelder C. Mesenchymal stem cells in renal repair. Kidney Int. 2005;68(5):2413-2419.
  • Lameire N, Van Biesen W, Vanholder R. Biocompatibility in dialysis membranes. Nat Rev Nephrol. 2012;8(2):80-90.
  • Mathew AT, Fishbane S, Obi Y, Kalantar-Zadeh K. Preservation of residual kidney function in hemodialysis patients: reviving an old concept. Kidney Int. 2016;90(2):262-271. doi:10.1016/j.kint.2016.02.037.